论文部分内容阅读
本报讯来自美国糖尿病协会(ADA)第65届年会上公布的数据显示,与单纯使用口服降血糖药物治疗的患者相比,甘精胰岛素 (rDNA源)注射剂(法国赛诺菲-安万特公司研制)加常规口服抗糖尿病药物可更早、更显著地控制2型糖尿患者血
According to data released at the 65th Annual Meeting of the American Diabetes Association (ADA), insulin glargine (rDNA source) injection (French Sanofi-Avan Special company developed) plus conventional oral antidiabetic drugs earlier, more significantly control type 2 diabetes patients blood